A Phase 2 interventional study of letetresgene autoleucel (GSK3377794) and Cyclophosphamide in Neoplasms, sponsored by GlaxoSmithKline. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-11.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Liposarcoma, Myxoid with a site in United States — 7 open to participants now, 13 under way, none of them phase 3. Liposarcoma, Myxoid · United States.
Among the 29 studies in Liposarcoma, Myxoid with a site in United States, this one is the 17th largest by enrollment of the 28 interventional ones that give a count, is the only one that started in 2016, is one of 9 in phase 2, and was the 7th registered.
40 studies on the registry are indexed under Liposarcoma, Myxoid; 12 are open to participants now.
Browse Liposarcoma, Myxoid studies →7 of the 29 studies in Liposarcoma, Myxoid with a site in United States are open now. Recruiting first, the newest first:
Seth Pollack · Sites in United States
Ages 18–80
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Daiichi Sankyo · Sites in United States, Belgium, France and 2 more countries
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 16–80
St. Jude Children's Research Hospital · Sites in United States
Ages up to 30
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 8 Liposarcoma, Myxoid studies recruiting now, 5 set no upper age limit and 1 stops at 75 or younger; 2 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 13
First in 2007; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is below the median of 30 across 36 interventional studies indexed under Liposarcoma, Myxoid.
Median enrollment 26 across the 28 interventional studies. Of the 11 that completed or were terminated, 8 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 29 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
GlaxoSmithKline has 1 study filed under Liposarcoma, Myxoid — fewer than ten, so there is no comparison to draw.
2 of the studies in Liposarcoma, Myxoid with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06083883M.D. Anderson Cancer CenterPhase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1 | 2026-11-30 |
| NCT06414434Michael Wagner, MDBTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma | 2027-01-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 29 studies in Liposarcoma, Myxoid with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This trial will evaluate safety and efficacy of Letetresgene autoleucel (GSK3377794) in participants with advanced myxoid/round cell liposarcoma or high-grade myxoid liposarcoma.
New York esophageal antigen-1 (NY-ESO-1) and LAGE-1a antigens are tumor-associated proteins that have been found in several tumor types. Clinical trials using adoptively transferred T-cells directed against NY-ESO-1/LAGE-1a have shown objective responses. Letetresgene autoleucel (GSK3377794) is the first generation of NY-ESO-1 specific T-cell receptor (TCR) engineered T-cells. This protocol investigates Letetresgene autoleucel treatment in Human Leukocyte Antigen (HLA)-A*02+ participants with NY-ESO1+ advanced myxoid/round cell liposarcoma or high-grade myxoid liposarcoma.
40 studies on the registry are indexed under Liposarcoma, Myxoid; 12 are open to participants now.
This study's enrollment of 23 is below the median of 30 across 36 interventional studies indexed under Liposarcoma, Myxoid.
Browse Liposarcoma, Myxoid studies →GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
Compared within Liposarcoma, Myxoid, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive letetresgene autoleucel (GSK3377794), as a single intravenous (IV) infusion after completing lymphodepleting chemotherapy.
Drug: letetresgene autoleucel (GSK3377794) · Drug: Cyclophosphamide · Drug: Fludarabine
Letetresgene autoleucel (GSK3377794) as an IV infusion.
Cyclophosphamide will be used as a lymphodepleting chemotherapy.
Fludarabine will be used as a lymphodepleting chemotherapy.
Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Investigator Assessment
Overall response rate (ORR) defined as the percentage of participants with a confirmed complete response (CR) or confirmed partial response (PR) via investigator assessment per RECIST (Response Evaluation Criteria In Solid Tumors Criteria) v1.1 relative to the total number of participants in the analysis population. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters (mm). Confidence intervals (CI) were calculated using the exact (Clopper-Pearson) method.
Time frame: Up to 24 months
Best Overall Response (BOR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Investigator Assessment
The Best Overall Response (BOR) with confirmation for a participant is defined as the best confirmed response (Confirmed Complete Response \[CR\] \> Confirmed Partial Response \[PR\] \> Stable Disease \[SD\] \> Progressive Disease \[PD\] \> Not Evaluable \[NE\]) from first T cell infusion until disease progression or initiation of new anti-cancer therapy, whichever is earlier, as assessed by the investigator per RECIST v1.1 Criteria.
Time frame: Up to 24 months
Time to Response (TTR) Assessed by Investigator
Time to response was defined as the interval of time between the date of T-cell infusion and the first documented evidence of the confirmed response (PR or CR), in the subset of participants with a confirmed PR or CR as their best confirmed overall response. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm.
Time frame: Up to 24 months
Duration of Response (DOR) Assessed by Investigator
Duration of response was defined as the interval between the initial date of confirmed response (PR/CR) and the date of progressive disease or death among participants with a confirmed response per RECIST 1.1. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters. Kaplan-Meier Median and 95% confidence intervals are presented. Confidence intervals were calculated using the Brookmeyer-Crowley method.
Time frame: Up to 24 months
Progression Free Survival (PFS) Assessed by Investigator
Progression free survival was defined as the interval between the date of T cell infusion and the earliest date of disease progression or death due to any cause. Progressive disease (PD) is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. PFS based on responses assessed by investigator per RECIST v1.1 is presented. Kaplan-Meier Median and 95% confidence intervals are presented. Confidence intervals were calculated using the Brookmeyer-Crowley method.
Time frame: Up to 24 months
Best Overall Response (BOR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Independent Reviewer Assessment
The Best Overall Response (BOR) with confirmation for a participant is defined as the best confirmed response (Confirmed Complete Response \[CR\] \> Confirmed Partial Response \[PR\] \> Stable Disease \[SD\] \> Progressive Disease \[PD\] \> Not Evaluable \[NE\]) from first T cell infusion until disease progression or initiation of new anti-cancer therapy, whichever is earlier, as assessed by independent reviewer per RECIST v1.1 criteria.
Time frame: Up to 24 months
Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Independent Reviewer
Overall response rate (ORR) defined as the percentage of participants with a confirmed complete response (CR) or confirmed partial response (PR) via independent reviewer assessment per RECIST v1.1 relative to the total number of participants in the analysis population. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters (mm). Confidence intervals (CI) were calculated using the exact (Clopper-Pearson) method.
Time frame: Up to 24 months
Time to Response (TTR) Assessed by Independent Reviewer
Time to response was defined as the interval of time between the date of T-cell infusion and the first documented evidence of the confirmed response (PR or CR), in the subset of participants with a confirmed PR or CR as their best confirmed overall response. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm.
Time frame: Up to 24 months
Duration of Response (DOR) Assessed by Independent Reviewer
Duration of response was defined as the interval between the initial date of confirmed response (PR/CR) and the date of progressive disease or death among participants with a confirmed response per RECIST 1.1. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. Kaplan-Meier Median and 95% confidence intervals are presented. Confidence intervals were calculated using the Brookmeyer-Crowley method.
Time frame: Up to 24 months
Progression Free Survival (PFS) Assessed by Independent Reviewer
Progression free survival was defined as the interval between the date of T cell infusion and the earliest date of disease progression or death due to any cause. Progressive disease (PD) is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. PFS based on responses assessed by independent reviewer per RECIST v1.1 is presented. Kaplan-Meier Median and 95% confidence intervals are presented. Confidence intervals were calculated using the Brookmeyer-Crowley method.
Time frame: Up to 24 months
Number of Participants With Serious Adverse Events (SAEs) and Non-SAEs
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. SAE is defined as any untoward medical occurrence that, at any dose can result in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth or is medically significant or requires intervention to prevent one or the outcomes listed above.
Time frame: Up to 24 months
Number of Participants With Adverse Event of Special Interest (AESI)
An AESI may be of scientific and medical concern related to the treatment, monitored, and rapidly communicated by investigator to sponsor. The AESI included events of Cytokine release syndrome (CRS), Haematopoietic cytopenias (including pancytopenia and aplastic anaemia), Graft versus host disease (GvHD), Immune Effector-Cell Associated Neurotoxicity Syndrome (ICANS), and Guillain-Barre syndrome.
Time frame: Up to 24 months
Number of Participants With Any Grade Increase in Hematology Results at Worst-case Post-baseline
Blood samples were collected for the analysis of following hematology parameters: hemoglobin, lymphocytes, neutrophils, platelets, leukocytes. Laboratory parameters were graded according to National Cancer Institute-Common Toxicity Criteria for Adverse Events (NCI-CTCAE) version 4.0, where Grade1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Baseline is the most recent, non-missing value from a central laboratory within 7 days prior to the lymphodepleting chemotherapy. An increase in grade is defined as an increase in CTCAE grade relative to baseline grade. Data of number of participants with any grade increase at worst-case post-baseline (maximum grade increase post-baseline) is presented.
Time frame: Up to 24 months
Number of Participants With Any Grade Increase in Clinical Chemistry Results at Worst-case Post-baseline
Blood samples were collected for the analysis clinical chemistry parameters: glucose, albumin, alkaline phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, creatinine, potassium, magnesium, sodium, phosphate, calcium. Laboratory parameters were graded according to National Cancer Institute-Common Toxicity Criteria for Adverse Events (NCI-CTCAE) version 4.0, where Grade1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Baseline is the most recent, non-missing value from a central laboratory within 7 days prior to the lymphodepleting chemotherapy. An increase in grade is defined as an increase in CTCAE grade relative to baseline grade. Data of number of participants with any grade increase at worst-case post-baseline (maximum grade increase post-baseline) is presented.
Time frame: Up to 24 months
Number of Participants With Replication Competent Lentivirus (RCL)
RCL was monitored using a polymerase chain reaction (PCR)-based assay that detects and measures copies of the gene coding for the vector's envelope protein, namely vesicular stomatitis virus G protein (VSV-G).
Time frame: Day 1 (pre-infusion), and at Week 12, Week 24, and 1 year post-infusion
Number of Participants With Insertional Oncogenesis
Peripheral blood mononuclear cells (PBMC) samples were collected for monitoring insertional oncogenesis by PCR for gene modified cells in the blood. DNA from participant identified with \>1% PBMC at \>=1 year post T-cell infusion was sent for integration site analysis. Integration site analysis was used to assess the possibility of insertional oncogenesis. Participants with insertional oncogenesis were participants with any clones representing \>20% of the total.
Time frame: Up to 2 years
Number of Participants With Positive Anti-drug Antibodies (ADAs)
Serum samples were collected to analyze for the presence of ADAs using validated immunoassays.
Time frame: Up to 24 Months
Maximum Transgene Expansion (Cmax) of GSK3377794
Cmax was defined as peak cell expansion during the interventional phase. Blood samples were collected to measure Cmax.
Time frame: Day 2 to Day 15
Time to Cmax (Tmax)
Tmax was defined as time to peak cell expansion during the interventional phase. Blood samples were collected to measure Tmax.
Time frame: Day 2 to Day 15
Area Under the Time Curve From Zero to Time 28 Days AUC(0-28) of GSK3377794
Area under the cell expansion-time curve from first T-cell infusion to Day 28. Blood samples were collected to measure AUC (0-28 days).
Time frame: Up to 28 days
Change From Baseline in Electrocardiogram (ECG) Parameters- PR Interval, QRS Duration, QT Interval, QTcB Interval, QTcF Interval and RR Interval
Triplicate 12-Lead ECGs were collected at baseline visit and single ECGs at other timepoints. At each time point during the study ECG was taken using an ECG machine that automatically calculates the heart rate and measured the PR interval, QRS duration, QTcB, QTcF intervals, RR interval and uncorrected QT interval. Baseline is the most recent, non-missing value within 7 days prior to the lymphodepleting chemotherapy. Change from baseline was to be calculated by subtracting post-dose value from baseline value.
Time frame: Baseline, Day 1, Day 4 and Day 8
Change From Baseline in ECG Mean Heart Rate
Single 12-lead ECG was to be obtained at designated time points during the study using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTc intervals. Baseline is the most recent, non-missing value within 7 days prior to the lymphodepleting chemotherapy. Change from baseline was to be calculated by subtracting post-dose value from baseline value.
Time frame: Baseline, Day 1 (Pre-dose), Day 4 and Day 8
This was an open-label study evaluating the safety and tolerability of autologous T-Cells expressing enhanced T-cell receptors (TCRs) specific for New York esophageal squamous cell carcinoma (NY-ESO)-1 (letetresgene autoleucel, lete-cel, GSK3377794) in Human Leukocyte Antigen (HLA)-A\*02:01, HLA-A\*02:05 and/or HLA-A\*02:06 participants with Advanced Myxoid/ Round Cell Liposarcoma.
| Milestone | Reduced Lymphodepletion Dose Plus GSK3377794 | Standard Lymphodepletion Dose Plus GSK3377794 |
|---|---|---|
| Started | 13 | 10 |
| Received t-cell infusion | 10 | 10 |
| Completed | 9 | 8 |
| Not completed | 4 | 2 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Death-prior to t-cell infusion | 1 | 0 |
| Withdrew: Did not meet inclusion/exclusion | 1 | 0 |
| Withdrew: No measurable disease | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 |
Overall response rate (ORR) defined as the percentage of participants with a confirmed complete response (CR) or confirmed partial response (PR) via investigator assessment per RECIST (Response Evaluation Criteria In Solid Tumors Criteria) v1.1 relative to the total number of participants in the analysis population. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters (mm). Confidence intervals (CI) were calculated using the exact (Clopper-Pearson) method.
| Percentage of participants | Reduced Lymphodepletion Dose Plus GSK3377794 | Standard Lymphodepletion Dose Plus GSK3377794 |
|---|---|---|
| Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Investigator Assessment | 20 (2.5 to 55.6) | 40 (12.2 to 73.8) |
The Best Overall Response (BOR) with confirmation for a participant is defined as the best confirmed response (Confirmed Complete Response \[CR\] \> Confirmed Partial Response \[PR\] \> Stable Disease \[SD\] \> Progressive Disease \[PD\] \> Not Evaluable \[NE\]) from first T cell infusion until disease progression or initiation of new anti-cancer therapy, whichever is earlier, as assessed by the investigator per RECIST v1.1 Criteria.
| Participants | Reduced Lymphodepletion Dose Plus GSK3377794 | Standard Lymphodepletion Dose Plus GSK3377794 |
|---|---|---|
| Complete Response (CR) | 0 | 0 |
| Partial Response (PR) | 2 | 4 |
| Stable Disease (SD) | 8 | 5 |
| Progressive Disease (PD) | 0 | 1 |
| Not Evaluable (NE) | 0 | 0 |
Time to response was defined as the interval of time between the date of T-cell infusion and the first documented evidence of the confirmed response (PR or CR), in the subset of participants with a confirmed PR or CR as their best confirmed overall response. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm.
| Months | Reduced Lymphodepletion Dose Plus GSK3377794 | Standard Lymphodepletion Dose Plus GSK3377794 |
|---|---|---|
| Time to Response (TTR) Assessed by Investigator | 1.856 (0.920 to 2.793) | 1.938 (1.889 to 2.366) |
Duration of response was defined as the interval between the initial date of confirmed response (PR/CR) and the date of progressive disease or death among participants with a confirmed response per RECIST 1.1. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters. Kaplan-Meier Median and 95% confidence intervals are presented. Confidence intervals were calculated using the Brookmeyer-Crowley method.
| Months | Reduced Lymphodepletion Dose Plus GSK3377794 | Standard Lymphodepletion Dose Plus GSK3377794 |
|---|---|---|
| Duration of Response (DOR) Assessed by Investigator | 5.31 (1.87 to 8.74) | 7.47 (6.01 to NA) |
Progression free survival was defined as the interval between the date of T cell infusion and the earliest date of disease progression or death due to any cause. Progressive disease (PD) is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. PFS based on responses assessed by investigator per RECIST v1.1 is presented. Kaplan-Meier Median and 95% confidence intervals are presented. Confidence intervals were calculated using the Brookmeyer-Crowley method.
| Months | Reduced Lymphodepletion Dose Plus GSK3377794 | Standard Lymphodepletion Dose Plus GSK3377794 |
|---|---|---|
| Progression Free Survival (PFS) Assessed by Investigator | 5.36 (2.00 to 11.50) | 8.74 (0.89 to NA) |
The Best Overall Response (BOR) with confirmation for a participant is defined as the best confirmed response (Confirmed Complete Response \[CR\] \> Confirmed Partial Response \[PR\] \> Stable Disease \[SD\] \> Progressive Disease \[PD\] \> Not Evaluable \[NE\]) from first T cell infusion until disease progression or initiation of new anti-cancer therapy, whichever is earlier, as assessed by independent reviewer per RECIST v1.1 criteria.
| Participants | Reduced Lymphodepletion Dose Plus GSK3377794 | Standard Lymphodepletion Dose Plus GSK3377794 |
|---|---|---|
| Complete Response (CR) | 0 | 0 |
| Partial Response (PR) | 2 | 4 |
| Stable Disease (SD) | 8 | 3 |
| Progressive Disease (PD) | 0 | 0 |
| Not Evaluable (NE) | 0 | 3 |
Overall response rate (ORR) defined as the percentage of participants with a confirmed complete response (CR) or confirmed partial response (PR) via independent reviewer assessment per RECIST v1.1 relative to the total number of participants in the analysis population. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 millimeters (mm). Confidence intervals (CI) were calculated using the exact (Clopper-Pearson) method.
| Percentage of participants | Reduced Lymphodepletion Dose Plus GSK3377794 | Standard Lymphodepletion Dose Plus GSK3377794 |
|---|---|---|
| Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Independent Reviewer | 20 (2.5 to 55.6) | 40 (12.2 to 73.8) |
Time to response was defined as the interval of time between the date of T-cell infusion and the first documented evidence of the confirmed response (PR or CR), in the subset of participants with a confirmed PR or CR as their best confirmed overall response. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm.
| Months | Reduced Lymphodepletion Dose Plus GSK3377794 | Standard Lymphodepletion Dose Plus GSK3377794 |
|---|---|---|
| Time to Response (TTR) Assessed by Independent Reviewer | 2.366 (1.840 to 2.891) | 1.889 (1.413 to 1.938) |
Duration of response was defined as the interval between the initial date of confirmed response (PR/CR) and the date of progressive disease or death among participants with a confirmed response per RECIST 1.1. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Complete response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm. Kaplan-Meier Median and 95% confidence intervals are presented. Confidence intervals were calculated using the Brookmeyer-Crowley method.
| Months | Reduced Lymphodepletion Dose Plus GSK3377794 | Standard Lymphodepletion Dose Plus GSK3377794 |
|---|---|---|
| Duration of Response (DOR) Assessed by Independent Reviewer | NA (NA to NA) | 7.16 (4.57 to NA) |
Progression free survival was defined as the interval between the date of T cell infusion and the earliest date of disease progression or death due to any cause. Progressive disease (PD) is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. PFS based on responses assessed by independent reviewer per RECIST v1.1 is presented. Kaplan-Meier Median and 95% confidence intervals are presented. Confidence intervals were calculated using the Brookmeyer-Crowley method.
| Months | Reduced Lymphodepletion Dose Plus GSK3377794 | Standard Lymphodepletion Dose Plus GSK3377794 |
|---|---|---|
| Progression Free Survival (PFS) Assessed by Independent Reviewer | 4.67 (2.79 to NA) | 9.03 (5.32 to NA) |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. SAE is defined as any untoward medical occurrence that, at any dose can result in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth or is medically significant or requires intervention to prevent one or the outcomes listed above.
| Participants | Reduced Lymphodepletion Dose Plus GSK3377794 | Standard Lymphodepletion Dose Plus GSK3377794 |
|---|---|---|
| SAEs | 5 | 7 |
| Non-SAEs | 13 | 10 |
An AESI may be of scientific and medical concern related to the treatment, monitored, and rapidly communicated by investigator to sponsor. The AESI included events of Cytokine release syndrome (CRS), Haematopoietic cytopenias (including pancytopenia and aplastic anaemia), Graft versus host disease (GvHD), Immune Effector-Cell Associated Neurotoxicity Syndrome (ICANS), and Guillain-Barre syndrome.
| Participants | Reduced Lymphodepletion Dose Plus GSK3377794 | Standard Lymphodepletion Dose Plus GSK3377794 |
|---|---|---|
| Participants with any AESI | 10 | 10 |
| Cytokine release syndrome | 6 | 10 |
| Haematopoietic cytopenias (including pancytopenia and aplastic anaemia) | 10 | 10 |
Blood samples were collected for the analysis of following hematology parameters: hemoglobin, lymphocytes, neutrophils, platelets, leukocytes. Laboratory parameters were graded according to National Cancer Institute-Common Toxicity Criteria for Adverse Events (NCI-CTCAE) version 4.0, where Grade1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Baseline is the most recent, non-missing value from a central laboratory within 7 days prior to the lymphodepleting chemotherapy. An increase in grade is defined as an increase in CTCAE grade relative to baseline grade. Data of number of participants with any grade increase at worst-case post-baseline (maximum grade increase post-baseline) is presented.
| Participants | Reduced Lymphodepletion Dose Plus GSK3377794 | Standard Lymphodepletion Dose Plus GSK3377794 |
|---|---|---|
| Hemoglobin Anemia | 9 | 10 |
| Lymphocyte count decreased | 10 | 10 |
| Neutrophils | 10 | 10 |
| Platelets | 9 | 10 |
| Leukocytes | 10 | 10 |
Blood samples were collected for the analysis clinical chemistry parameters: glucose, albumin, alkaline phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, creatinine, potassium, magnesium, sodium, phosphate, calcium. Laboratory parameters were graded according to National Cancer Institute-Common Toxicity Criteria for Adverse Events (NCI-CTCAE) version 4.0, where Grade1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Baseline is the most recent, non-missing value from a central laboratory within 7 days prior to the lymphodepleting chemotherapy. An increase in grade is defined as an increase in CTCAE grade relative to baseline grade. Data of number of participants with any grade increase at worst-case post-baseline (maximum grade increase post-baseline) is presented.
| Participants | Reduced Lymphodepletion Dose Plus GSK3377794 | Standard Lymphodepletion Dose Plus GSK3377794 |
|---|---|---|
| Glucose Hyperglycemia | 5 | 8 |
| Glucose Hypoglycemia | 1 | 4 |
| Albumin | 9 | 9 |
| Alkaline Phosphatase | 4 | 6 |
| ALT | 7 | 7 |
| AST | 8 | 8 |
| Bilirubin | 3 | 2 |
| Creatinine | 4 | 2 |
| Potassium Hyperkalemia | 1 | 1 |
| Potassium Hypokalemia | 5 | 9 |
| Magnesium Hypermagnesemia | 5 | 2 |
| Magnesium Hypomagnesemia | 2 | 6 |
| Phosphate | 9 | 10 |
| Sodium Hypernatremia | 2 | 1 |
| Sodium Hyponatremia | 8 | 9 |
| Calcium Corrected for Albumin Hypercalcemia | 2 | 1 |
| Calcium Corrected for Albumin Hypocalcemia | 1 | 7 |
RCL was monitored using a polymerase chain reaction (PCR)-based assay that detects and measures copies of the gene coding for the vector's envelope protein, namely vesicular stomatitis virus G protein (VSV-G).
| Participants | Reduced Lymphodepletion Dose Plus GSK3377794 | Standard Lymphodepletion Dose Plus GSK3377794 |
|---|---|---|
| Number of Participants With Replication Competent Lentivirus (RCL) | 0 | 0 |
Peripheral blood mononuclear cells (PBMC) samples were collected for monitoring insertional oncogenesis by PCR for gene modified cells in the blood. DNA from participant identified with \>1% PBMC at \>=1 year post T-cell infusion was sent for integration site analysis. Integration site analysis was used to assess the possibility of insertional oncogenesis. Participants with insertional oncogenesis were participants with any clones representing \>20% of the total.
| Participants | Reduced Lymphodepletion Dose Plus GSK3377794 | Standard Lymphodepletion Dose Plus GSK3377794 |
|---|---|---|
| Number of Participants With Insertional Oncogenesis | 0 | 0 |
Serum samples were collected to analyze for the presence of ADAs using validated immunoassays.
| Participants | Reduced Lymphodepletion Dose Plus GSK3377794 | Standard Lymphodepletion Dose Plus GSK3377794 |
|---|---|---|
| Number of Participants With Positive Anti-drug Antibodies (ADAs) | 0 | 0 |
Cmax was defined as peak cell expansion during the interventional phase. Blood samples were collected to measure Cmax.
| Copies per microgram genomic DNA | Reduced Lymphodepletion Dose Plus GSK3377794 | Standard Lymphodepletion Dose Plus GSK3377794 |
|---|---|---|
| Maximum Transgene Expansion (Cmax) of GSK3377794 | 66991.71 ± 127.0 | 108485.91 ± 53.4 |
Tmax was defined as time to peak cell expansion during the interventional phase. Blood samples were collected to measure Tmax.
| Days | Reduced Lymphodepletion Dose Plus GSK3377794 | Standard Lymphodepletion Dose Plus GSK3377794 |
|---|---|---|
| Time to Cmax (Tmax) | 2 (2 to 13) | 4 (2 to 15) |
Area under the cell expansion-time curve from first T-cell infusion to Day 28. Blood samples were collected to measure AUC (0-28 days).
| Days*copies per microgram genomic DNA | Reduced Lymphodepletion Dose Plus GSK3377794 | Standard Lymphodepletion Dose Plus GSK3377794 |
|---|---|---|
| Area Under the Time Curve From Zero to Time 28 Days AUC(0-28) of GSK3377794 | 727135.6 ± 223.9 | 1142798.27 ± 70.7 |
Triplicate 12-Lead ECGs were collected at baseline visit and single ECGs at other timepoints. At each time point during the study ECG was taken using an ECG machine that automatically calculates the heart rate and measured the PR interval, QRS duration, QTcB, QTcF intervals, RR interval and uncorrected QT interval. Baseline is the most recent, non-missing value within 7 days prior to the lymphodepleting chemotherapy. Change from baseline was to be calculated by subtracting post-dose value from baseline value.
| Milliseconds (msec) | Reduced Lymphodepletion Dose Plus GSK3377794 | Standard Lymphodepletion Dose Plus GSK3377794 |
|---|---|---|
| PR Interval, BASELINE | 152.9 ± 14.59 | 142 ± 12.72 |
| PR Interval, DAY 1 | -2.3 ± 8.66 | -2.2 ± 9.82 |
| PR Interval, DAY 4 | -10.7 ± 17.18 | -4 ± 12.96 |
| PR Interval, DAY 8 | -8.1 ± 14.9 | 1 ± 9.32 |
| QRS Duration, BASELINE | 91.2 ± 16.53 | 86.1 ± 15.01 |
| QRS Duration, DAY 1 | 2.8 ± 18.87 | 0.9 ± 6.49 |
| QRS Duration, DAY 4 | 2.3 ± 20.43 | 0.8 ± 5.75 |
| QRS Duration, DAY 8 | -2.7 ± 25.75 | -1 ± 5.86 |
| QT Interval, BASELINE | 401.1 ± 11.71 | 389.3 ± 33.57 |
| QT Interval, DAY 1 | -6.4 ± 23.51 | -8.1 ± 33.74 |
| QT Interval, DAY 4 | -49.4 ± 38.59 | -72.5 ± 47.65 |
| QT Interval, DAY 8 | -16.7 ± 21.63 | -4.4 ± 43.41 |
| QTcB Interval, BASELINE | 427 ± 4.24 | 423.3 ± 19.35 |
| QTcB Interval, DAY 1 | 28 ± NA | 36.3 ± 34.03 |
| QTcB Interval, DAY 4 | 10 ± 24.04 | 8 ± 25.46 |
| QTcB Interval, DAY 8 | 1 ± NA | 47 ± 50.27 |
| QTcF Interval, BASELINE | 429.9 ± 23.75 | 425.3 ± 16.18 |
| QTcF Interval, DAY 1 | -10.1 ± 21.06 | 1.3 ± 17.36 |
| QTcF Interval, DAY 4 | -25.3 ± 36.62 | 3.3 ± 31.1 |
| QTcF Interval, DAY 8 | -7.5 ± 22.63 | 16.2 ± 39.96 |
| RR Interval, BASELINE | 842.6 ± 144.62 | 807.6 ± 166.39 |
| RR Interval, DAY 1 | -15.8 ± 98.77 | 5.3 ± 43.1 |
| RR Interval, DAY 4 | -162.5 ± 179.21 | -188 ± 11.31 |
| RR Interval, DAY 8 | -71.6 ± 109.66 | -138.5 ± 77.72 |
Single 12-lead ECG was to be obtained at designated time points during the study using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTc intervals. Baseline is the most recent, non-missing value within 7 days prior to the lymphodepleting chemotherapy. Change from baseline was to be calculated by subtracting post-dose value from baseline value.
| Beats per minute (beats/minute) | Reduced Lymphodepletion Dose Plus GSK3377794 | Standard Lymphodepletion Dose Plus GSK3377794 |
|---|---|---|
| BASELINE | 73.0 ± 12.34 | 78.0 ± 20.06 |
| DAY 1 | 1.6 ± 10.08 | 4.8 ± 14.20 |
| DAY 4 | 20.1 ± 16.34 | 38.9 ± 21.95 |
| DAY 8 | 5.4 ± 12.72 | 9.1 ± 16.37 |
Collected over All cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected up to 30 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Reduced Lymphodepletion Dose Plus GSK3377794 | 5/13 (38.5%) | 5/13 (38.5%) | 13/13 (100%) |
| Standard Lymphodepletion Dose Plus GSK3377794 | 0/10 (0%) | 7/10 (70%) | 10/10 (100%) |
| Event | Reduced Lymphodepletion Dose Plus GSK3377794 | Standard Lymphodepletion Dose Plus GSK3377794 |
|---|---|---|
| Cytokine release syndromeImmune system disorders | 3/13 | 5/10 |
| Rash maculo-papularSkin and subcutaneous tissue disorders | 0/13 | 3/10 |
| PyrexiaGeneral disorders | 0/13 | 1/10 |
| PneumoniaInfections and infestations | 0/13 | 1/10 |
| Neutrophil count decreasedInvestigations | 0/13 | 1/10 |
| Platelet count decreasedInvestigations | 1/13 | 1/10 |
| Transaminases increasedInvestigations | 0/13 | 1/10 |
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/13 | 1/10 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 1/13 | 1/10 |
| AnaemiaBlood and lymphatic system disorders | 1/13 | 0/10 |
| Event | Reduced Lymphodepletion Dose Plus GSK3377794 | Standard Lymphodepletion Dose Plus GSK3377794 |
|---|---|---|
| White blood cell count decreasedInvestigations | 7/13 | 10/10 |
| AnaemiaBlood and lymphatic system disorders | 6/13 | 9/10 |
| NauseaGastrointestinal disorders | 8/13 | 8/10 |
| PyrexiaGeneral disorders | 8/13 | 8/10 |
| Neutrophil count decreasedInvestigations | 7/13 | 8/10 |
| HypophosphataemiaMetabolism and nutrition disorders | 6/13 | 8/10 |
| Lymphocyte count decreasedInvestigations | 10/13 | 7/10 |
| FatigueGeneral disorders | 8/13 | 7/10 |
| Platelet count decreasedInvestigations | 4/13 | 7/10 |
| DiarrhoeaGastrointestinal disorders | 5/13 | 6/10 |
| Age, Continuous(YEARS) | Reduced Lymphodepletion Dose Plus GSK3377794 | Standard Lymphodepletion Dose Plus GSK3377794 | Total |
|---|---|---|---|
| Mean | 50.0 ± 6.79 | 46.0 ± 11.61 | 48.3 ± 9.19 |
| Sex: Female, Male(Participants) | Reduced Lymphodepletion Dose Plus GSK3377794 | Standard Lymphodepletion Dose Plus GSK3377794 | Total |
|---|---|---|---|
| Female | 6 | 3 | 9 |
| Male | 7 | 7 | 14 |
| Race/Ethnicity, Customized(Participants) | Reduced Lymphodepletion Dose Plus GSK3377794 | Standard Lymphodepletion Dose Plus GSK3377794 | Total |
|---|---|---|---|
| Black or African American | 1 | 0 | 1 |
| Other: More than one race | 1 | 0 | 1 |
| White | 11 | 10 | 21 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Dec 2016 to primary completion in Nov 2021, 58 months.
Results were first posted in Nov 2022, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Letetresgene autoleucel